CDKN2A and sarcoma: Although p16/p19−/−×AKE mice had a similar incidence (24%; 16/67 animals) and latency of tumor formation (median 9 weeks, range 6–25 weeks) to the p16/p19−/−×BKE strain, a striking increase in sarcoma formation distant to the injection site was observed.